CD Skripsi
Gambaran Respons Dan Efek Samping Kemoterapi Bleomisin, Etoposid Sisplatin (Bep) Pada Karsinoma Testis Di Rsud Arifin Achmad Provinsi Riau Periode 2019-2023
Testicular carcinoma is a type of cancer that affects men of productive age and generally has a good prognosis if treated properly. The BEP chemotherapy regimen (Bleomycin, Etoposide, and Cisplatin) is a primary therapy commonly used in the management of this cancer. This study aimed to describe the therapeutic response and side effects of BEP chemotherapy in testicular carcinoma patients at Arifin Achmad General Hospital, Pekanbaru, during the period 2019–2023. This is a descriptive study using a retrospective-prospective cohort design, involving secondary data obtained from medical records and prospective follow-up data collected from post-chemotherapy control visits. Out of a total of 62 testicular carcinoma patients, 34 patients (54.8%) underwent BEP chemotherapy. The majority of patients had a histopathological diagnosis of seminoma (76.2%) and the most common stage was stage IIIC (38.1%). The chemotherapy response showed that most patients achieved a complete response (52.4%), followed by disease progression (28.6%), and partial response (9,5%). The most frequently reported short-term side effects were nausea and vomiting (85.7%), followed by fatigue (76.2%) and anorexia (71.4%). The most common long-term side effects were nephrotoxicity (14.3%) and pulmonary toxicity (9.5%). In conclusion, BEP chemotherapy demonstrated effective clinical outcomes in the majority of testicular carcinoma patients. Although various side effects were observed, most were tolerable and manageable. These findings reinforce the role of BEP as a standard treatment option, while also highlighting the need for careful monitoring and supportive care to minimize adverse effects and optimize patient quality of life.
Keywords: BEP chemotherapy, Side effects, Testicular carcinoma, Therapeutic response
Tidak tersedia versi lain